Pleiotropic Effect of Lovastatin, With and Without Cholestyramine, in the Post Coronary Artery Bypass Graft (Post CABG) Trial

American Journal of Cardiology

Volumn 102, Issue 8, 2008, Pages 1023-1027

  Domanski, Michael ^a   Tian, Xin ^a   Fleg, Jerome ^a   Coady, Sean ^a   Gosen, Christine ^a   Kirby, Ruth ^a   Sachdev, Vandana ^a   Knatterud, Genell ^b   Braunwald, Eugene ^c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b MARYLAND MEDICAL RESEARCH INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTYRAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG MECHANISM; HUMAN; MAJOR CLINICAL STUDY; PLEIOTROPY; PRIORITY JOURNAL; SAPHENOUS VEIN GRAFT;

ANTICHOLESTEREMIC AGENTS; CHOLESTYRAMINE; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 54549110224     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.05.053     Document Type: Article

References (30)

1. Cannon C., Braunwald E., McCabe C., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A.M., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
2. Pedersen T., Faergeman O., Kastelein J., Olsson A.G., Tikkanen M.J., Holme I., Larsen M.L., Bendiksen F.S., Lindahl C., Szarek M., and Tsai J. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized, controlled trial. JAMA 294 (2005) 2437-2445
3. La Rosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., Wenger N.K., and Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
4. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97 (1998) 1440-1445
5. Gotto Jr. A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., Jou J.Y., Langendorfer A., Beere P.A., Watson D.J., Downs J.R., and de Cani J.S. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101 (2000) 477-484
6. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., Simes R., and Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366 (2005) 1267-1278
7. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., Crowe T., Howard G., Cooper C.J., Brodie B., Grines C.L., DeMaria A.N., and REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
8. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., Davignon J., Erbel R., Fruchart J.C., Tardif J.C., et al., ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
9. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336 (1997) 153-162
10. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109 suppl (2004) III39-III43
11. Ray K.K., and Cannon C.P. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 46 (2005) 1425-1433
12. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E., and Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98 (1998) 839-844
13. Albert M.A., Danielson E., Rifai N., and Ridker P.M. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 (2001) 64-70
14. Landmesser U., Bahlmann F., Mueller M., Spiekermann S., Kirschhoff N., Schuls S., Manes C., Fischer D., de Groot K., Fliser D., et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111 (2005) 2356-2363
15. Marchesi S., Lupattelli G., Siepi D., Schillaci G., Vaudo G., Roscini A.R., Sinzinger H., and Mannarino E. Short-term atorvastatin treatment improves endothelial function in hypercholeterolemic women. J Cardiovasc Pharmacol 36 (2000) 617-621
16. Guven G.S., Atalar E., Yavuz B., Beyazit Y., Kekilli M., Kiliarslan A., Sahiner L., Oz G., Ozer N., Aksoyek S., Hazned Aroglu I.C., and Sozen T. Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholesterolemia. J Natl Med Assoc 98 (2006) 627-630
17. Freeman D.J., Norrie J., Sattar N., Neely R.D., Cobbe S.M., Ford I., Isles C., Lorimer A.R., Macfarlane P.W., McKillop J.H., et al. Pravastatin and the development of diabetes: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103 (2001) 357-362
18. Buemi M., Senatore M., Corica F., Aloisi C., Romeo A., Cavallaro E., Floccari F., Tramontana D., and Frisina N. Statins and progressive renal disease. Med Res Rev 22 (2002) 76-84
19. Scirica B., Morrow D., Cannon C., Ray K.K., Sabatine M.S., Jarolim P., Shui A., McCabe C.H., Braunwald E., and PROVE-IT-TIMI 22 Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE-IT-TIMI 22 study. J Am Coll Cardiol 47 (2006) 2326-2331
20. Foody J., Shah R., Galusha D., Masoudi F., Havranek E., and Krumholz H. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113 (2006) 1086-1092
21. Liang K.Y., and Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 73 (1986) 13-22
22. Domanski M.J., Borkowf C.B., Campeau L., Knatterud G.L., White C., Hoogwerf B., Rosenberg Y., Geller N., and Post CABG Trial Investigators. Prognostic factors for atherosclerosis progression in saphenous vein grafts: the Post Coronary Artery Bypass Graft (Post CABG) trial. J Am Coll Cardiol 36 (2000) 1877-1883
23. Liao J. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110 (2002) 285-288
24. Tomas M., Senti M., Garcia-Faria F., Vila J., Torrents A., Covas M., and Marrrugat J. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 20 (2000) 2113-2119
25. Resch U., Tatzber F., Budinsky A., and Singzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 612 (2006) 262-274
26. Leu H.B., Chen J.W., Wu T.C., Ding Y.A., Lin S.J., and Charng M.J. Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia. Clin Cardiol 28 (2005) 423-428
27. Fichtlscherer S., Breuer S., Heeschen C., Dimmeler S., and Zeiher A.M. Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. J Am Coll Cardiol 44 (2004) 44-49
28. Fuhrman B., Koren L., Volkava N., Keidar S., Hayek T., and Aviram M. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized LDL by differentiating monocytes. Atherosclerosis 164 (2002) 179-185
29. Cha J.K., Jeong M.H., and Kim J.W. Statin reduces the platelet P-selectin expression in atherosclerotic ischemic stroke. J Thromb Thrombolysis 18 (2004) 39-42
30. Casani L., Sanchez-Gomez S., Vilahur G., and Badimon L. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thromb Haemost 94 (2005) 1035-1041